433 related articles for article (PubMed ID: 26968141)
21. Magnetic resonance imaging features in triple-negative breast cancer: comparison with luminal and HER2-overexpressing tumors.
Costantini M; Belli P; Distefano D; Bufi E; Matteo MD; Rinaldi P; Giuliani M; Petrone G; Magno S; Bonomo L
Clin Breast Cancer; 2012 Oct; 12(5):331-9. PubMed ID: 23040001
[TBL] [Abstract][Full Text] [Related]
22. Radiomic Signatures Derived from Diffusion-Weighted Imaging for the Assessment of Breast Cancer Receptor Status and Molecular Subtypes.
Leithner D; Bernard-Davila B; Martinez DF; Horvat JV; Jochelson MS; Marino MA; Avendano D; Ochoa-Albiztegui RE; Sutton EJ; Morris EA; Thakur SB; Pinker K
Mol Imaging Biol; 2020 Apr; 22(2):453-461. PubMed ID: 31209778
[TBL] [Abstract][Full Text] [Related]
23. Imaging features of triple-negative breast cancers according to androgen receptor status.
Candelaria RP; Adrada BE; Wei W; Thompson AM; Santiago L; Lane DL; Huang ML; Arribas EM; Rauch GM; Symmans WF; Gilcrease MZ; Huo L; Lim B; Ueno NT; Moulder SL; Yang WT
Eur J Radiol; 2019 May; 114():167-174. PubMed ID: 31005169
[TBL] [Abstract][Full Text] [Related]
24. Intratumoral heterogeneity of the distribution of kinetic parameters in breast cancer: comparison based on the molecular subtypes of invasive breast cancer.
Yamaguchi K; Abe H; Newstead GM; Egashira R; Nakazono T; Imaizumi T; Irie H
Breast Cancer; 2015 Sep; 22(5):496-502. PubMed ID: 24402638
[TBL] [Abstract][Full Text] [Related]
25. Association between MRI Features and Standardized Uptake Value of 18F-FDG PET/CT in Triple-Negative Breast Cancer.
Choi BB; Lee JS; Kim KH
Oncol Res Treat; 2018; 41(11):706-711. PubMed ID: 30321870
[TBL] [Abstract][Full Text] [Related]
26. Radiomic analysis reveals DCE-MRI features for prediction of molecular subtypes of breast cancer.
Fan M; Li H; Wang S; Zheng B; Zhang J; Li L
PLoS One; 2017; 12(2):e0171683. PubMed ID: 28166261
[TBL] [Abstract][Full Text] [Related]
27. Vascular characterisation of triple negative breast carcinomas using dynamic MRI.
Li SP; Padhani AR; Taylor NJ; Beresford MJ; Ah-See ML; Stirling JJ; d'Arcy JA; Collins DJ; Makris A
Eur Radiol; 2011 Jul; 21(7):1364-73. PubMed ID: 21258931
[TBL] [Abstract][Full Text] [Related]
28. Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set.
Cain EH; Saha A; Harowicz MR; Marks JR; Marcom PK; Mazurowski MA
Breast Cancer Res Treat; 2019 Jan; 173(2):455-463. PubMed ID: 30328048
[TBL] [Abstract][Full Text] [Related]
29. Pattern of hormone receptors and human epidermal growth factor receptor 2 status in sub-Saharan breast cancer cases: Private practice experience.
Nwafor CC; Keshinro SO
Niger J Clin Pract; 2015; 18(4):553-8. PubMed ID: 25966732
[TBL] [Abstract][Full Text] [Related]
30. Radiomic features of Pk-DCE MRI parameters based on the extensive Tofts model in application of breast cancer.
Zhou X; Gao F; Duan S; Zhang L; Liu Y; Zhou J; Bai G; Tao W
Phys Eng Sci Med; 2020 Jun; 43(2):517-524. PubMed ID: 32524436
[TBL] [Abstract][Full Text] [Related]
31. A multiparametric approach to predict triple-negative breast cancer including parameters derived from ultrafast dynamic contrast-enhanced MRI.
Ohashi A; Kataoka M; Iima M; Honda M; Ota R; Urushibata Y; Dominik Nickel M; Toi M; Zackrisson S; Nakamoto Y
Eur Radiol; 2023 Nov; 33(11):8132-8141. PubMed ID: 37286791
[TBL] [Abstract][Full Text] [Related]
32. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
[TBL] [Abstract][Full Text] [Related]
33. Dynamic Contrast-enhanced Breast MRI for Evaluating Residual Tumor Size after Neoadjuvant Chemotherapy.
Kim SY; Cho N; Park IA; Kwon BR; Shin SU; Kim SY; Lee SH; Chang JM; Moon WK
Radiology; 2018 Nov; 289(2):327-334. PubMed ID: 30152744
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?
Agarwal G; Nanda G; Lal P; Mishra A; Agarwal A; Agrawal V; Krishnani N
World J Surg; 2016 Jun; 40(6):1362-72. PubMed ID: 26842691
[TBL] [Abstract][Full Text] [Related]
35. Preliminary study on discriminating HER2 2+ amplification status of breast cancers based on texture features semi-automatically derived from pre-, post-contrast, and subtraction images of DCE-MRI.
Song L; Lu H; Yin J
PLoS One; 2020; 15(6):e0234800. PubMed ID: 32555662
[TBL] [Abstract][Full Text] [Related]
36. Multilevel analysis of spatiotemporal association features for differentiation of tumor enhancement patterns in breast DCE-MRI.
Lee SH; Kim JH; Cho N; Park JS; Yang Z; Jung YS; Moon WK
Med Phys; 2010 Aug; 37(8):3940-56. PubMed ID: 20879557
[TBL] [Abstract][Full Text] [Related]
37. Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management: Single-institution experience and review of published literature.
Meattini I; Bicchierai G; Saieva C; De Benedetto D; Desideri I; Becherini C; Abdulcadir D; Vanzi E; Boeri C; Gabbrielli S; Lucci F; Sanchez L; Casella D; Bernini M; Orzalesi L; Vezzosi V; Greto D; Mangoni M; Bianchi S; Livi L; Nori J
Eur J Surg Oncol; 2017 Apr; 43(4):642-648. PubMed ID: 27889196
[TBL] [Abstract][Full Text] [Related]
38. Magnetic resonance (MR) features in triple negative breast cancer (TNBC) vs receptor positive cancer (nTNBC).
Angelini G; Marini C; Iacconi C; Mazzotta D; Moretti M; Picano E; Morganti R
Clin Imaging; 2018; 49():12-16. PubMed ID: 29120811
[TBL] [Abstract][Full Text] [Related]
39. Prediction of the clinicopathological subtypes of breast cancer using a fisher discriminant analysis model based on radiomic features of diffusion-weighted MRI.
Ni M; Zhou X; Liu J; Yu H; Gao Y; Zhang X; Li Z
BMC Cancer; 2020 Nov; 20(1):1073. PubMed ID: 33167903
[TBL] [Abstract][Full Text] [Related]
40. US-localized diffuse optical tomography in breast cancer: comparison with pharmacokinetic parameters of DCE-MRI and with pathologic biomarkers.
Kim MJ; Su MY; Yu HJ; Chen JH; Kim EK; Moon HJ; Choi JS
BMC Cancer; 2016 Feb; 16():50. PubMed ID: 26833069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
